Pfizer boosts profit view as it battles for obesity startup
Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for ...
Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for ...
Pfizer on Friday (Oct 31) filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement obligations ...
Your support helps us to tell the storyFrom reproductive rights to climate change to Big Tech, The Independent is on ...
New Delhi: All India Institute of Medical Sciences (AIIMS), Delhi, Director M Srinivas on Sunday said cases of obesity are ...
The price for a month’s supply of the starter dose of Wegovy will be 1,400 yuanNovo Nordisk said on Monday ...
Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted on Wednesday (Nov ...
Article contentHeading into a gluttonous time of year in the U.S. with Halloween, Thanksgiving and Christmas on deck, it might ...
A new generation of obesity drugs often delivers dramatic weight loss, but many patients wonder what happens when they stop ...
Massive demand for diabetes and weight loss drugs made by Danish pharmaceutical group Novo Nordisk have turned it into Europe's ...
A player is pictured during his "Futbol de Peso" (Soccer of Weight ) league soccer match, a league for obese ...
The NY Journals pride themselves on assembling a proficient and dedicated team comprising seasoned journalists and editors. This collective commitment drives us to provide our esteemed readership with nothing short of the most comprehensive, accurate, and captivating news coverage available.
Transcending the bounds of New York City to encompass a broader scope, we ensure that our audience remains well-informed and engaged with the latest developments, both locally and beyond.
© 2025 The New York Journals. All Rights Reserved.